American Trust Sells 845 Shares of Zoetis Inc. (NYSE:ZTS)

American Trust decreased its position in shares of Zoetis Inc. (NYSE:ZTS) by 4.2% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 19,491 shares of the company’s stock after selling 845 shares during the quarter. American Trust’s holdings in Zoetis were worth $3,379,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in ZTS. Webster Bank N. A. raised its holdings in Zoetis by 89.1% during the 1st quarter. Webster Bank N. A. now owns 174 shares of the company’s stock valued at $29,000 after acquiring an additional 82 shares during the period. Quarry LP boosted its holdings in Zoetis by 273.2% in the 2nd quarter. Quarry LP now owns 209 shares of the company’s stock valued at $36,000 after purchasing an additional 153 shares during the period. Neo Ivy Capital Management purchased a new stake in shares of Zoetis in the fourth quarter worth $40,000. LRI Investments LLC purchased a new stake in shares of Zoetis in the 1st quarter valued at about $43,000. Finally, Hazlett Burt & Watson Inc. boosted its position in shares of Zoetis by 60.7% during the 1st quarter. Hazlett Burt & Watson Inc. now owns 270 shares of the company’s stock valued at $46,000 after acquiring an additional 102 shares during the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Stock Performance

Zoetis stock opened at $194.49 on Wednesday. The firm has a fifty day simple moving average of $186.64 and a two-hundred day simple moving average of $175.09. The company has a quick ratio of 2.09, a current ratio of 3.45 and a debt-to-equity ratio of 1.32. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $201.92. The company has a market capitalization of $88.74 billion, a PE ratio of 37.47, a P/E/G ratio of 2.99 and a beta of 0.88.

Zoetis (NYSE:ZTS) last released its earnings results on Tuesday, August 6th. The company reported $1.56 earnings per share for the quarter, beating analysts’ consensus estimates of $1.49 by $0.07. The company had revenue of $2.36 billion during the quarter, compared to analyst estimates of $2.31 billion. Zoetis had a return on equity of 50.67% and a net margin of 26.29%. Zoetis’s revenue for the quarter was up 8.3% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.41 EPS. Research analysts expect that Zoetis Inc. will post 5.84 EPS for the current year.

Wall Street Analyst Weigh In

ZTS has been the topic of several research analyst reports. Piper Sandler upped their price objective on shares of Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 14th. Stifel Nicolaus increased their price target on shares of Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a report on Wednesday, September 18th. Argus raised shares of Zoetis to a “strong-buy” rating in a report on Friday, August 9th. Finally, BTIG Research upped their target price on shares of Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a research report on Monday, August 12th. Nine research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Zoetis presently has a consensus rating of “Buy” and a consensus price target of $220.38.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.